Patients who have any life-threatening illness, medical condition, or organ system dysfunction which, in the investigators opinion, could compromise the subjects safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at risk are not eligible
Life-threatening illness or severe organ system dysfunction, such as uncontrolled congestive heart failure or chronic obstructive pulmonary disease, or other reasons including laboratory abnormalities, which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ASTX, or compromise completion of the study or integrity of the study outcomes.
A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of acalabrutinib, or put the study outcomes at undue risk
Life-threatening illness or organ system dysfunction compromising safety evaluation
Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigators opinion, could compromise the subjects safety or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigators opinion, could compromise the subjects safety or put the study outcomes at undue risk
A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of study drugs, or put the study outcomes at undue risk.
Any life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subjects safety or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigators opinion, could compromise the subjects safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk
Any illness, medical condition or organ system dysfunction which, in the investigators opinion, could compromise the subjects safety, interfere with the absorption or metabolism of lenalidomide, or put the study outcomes at undue risk
Subjects with life-threatening illnesses other than MDS, uncontrolled medical conditions or organ system dysfunction which, in the investigators opinion, could compromise the subjects safety, or put the study outcomes at risk
Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigators opinion, could compromise the subjects safety or put the study outcomes at undue risk
Any life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the patients safety
Any life threatening illness, medical condition, or organ system dysfunction that, in the investigators opinion, could compromise the subjects safety or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk
Any illness, medical condition or organ system dysfunction which, in the investigators opinion, could compromise the subjects safety, interfere with the absorption or metabolism of venetoclax and lenalidomide, or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigators opinion, could compromise the subjects safety or put the study outcomes at undue risk
A life-threatening illness, medical condition or organ system dysfunction which, in the investigators opinion, could compromise the subjects safety, interfere with the absorption or metabolism of ibrutinib, or put the study outcomes at undue risk
Any life-threatening illness, known autoimmune disease, medical condition, or organ system dysfunction that, in the investigators opinion, could compromise the subjects safety or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigators opinion, could compromise the subjects safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigators opinion, could compromise the subjects safety, interfere with the absorption or metabolism of enzalutamide, or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigators opinion, could compromise the subjects safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigators opinion, could compromise the subjects safety or put the study outcomes at undue risk
A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of PCI- PO, or put the study outcomes at undue risk
A life threatening illness, medical condition or organ system dysfunction which, in the investigators opinion, could compromise the subjects safety or interfere with the absorption or metabolism of pembrolizumab
Current life-threatening illness, medical condition, or organ-system dysfunction that could compromise patient safety or put the study at risk
Researchers think that any life-threatening illness, condition or organ system dysfunction can damage the safety of subjects
Any life-threatening illness, medical condition, or organ system dysfunction, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, active autoimmune disorder, or psychiatric illness/social situations that, in the investigators opinion, could compromise the subjects safety or put the study outcomes at undue risk
Subjects with a life-threatening illness, medical condition or organ system dysfunction, or other reasons which, in the investigators opinion, could compromise the subjects safety, interfere with or compromise the integrity of the study outcomes including incomplete recovery from the acute effects from any prior anti-neoplastic therapy
Current life-threatening illness, medical condition, or organ system dysfunction, which, in the investigators opinion, could compromise the patients safety, or put the study at risk
Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigators opinion, could compromise the patients safety, or put the study at undue risk; patients with suspicious radiologic evidence of aspergillosis infection (i.e., chest computed tomography [CT] and/or brain magnetic resonance imaging [MRI]) will not be eligible unless confirmatory laboratory testing of beta-D glucan and aspergillus antigen are negative
Life-threatening illness, significant organ system dysfunction, or other condition that, in the investigator's opinion, could compromise subject safety or the integrity of the study outcomes, or interfere with the absorption or metabolism of ASTX.
A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of study drugs, or put the study outcomes at undue risk.
Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigators opinion, could compromise the patients safety, or put the study at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigators opinion, could compromise the subjects safety, interfere with the absorption or metabolism of lenalidomide capsules, or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigators opinion, could compromise the subjects safety or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigators opinion, could compromise the subjects safety or put the study outcomes at undue risk
Any life-threatening illness, medical condition, organ system dysfunction, need for profound anticoagulation, or bleeding disorder, which, in the investigator's opinion, could compromise the subject's safety
Patients with any life threatening illness, medical condition or organ system dysfunction that in the opinion of the investigator could compromise the subjects safety, interfere with absorption of metabolism of study drugs or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigators opinion could interfere with the absorption or metabolism of ibrutinib
Any medical condition or organ system dysfunction which, in the investigators opinion, could compromise the patients safety, interfere with the absorption or metabolism of ibrutinib
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigators opinion, could compromise the subjects safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk, including but not limited to:\r\n* Moderate to severe hepatic impairment (Child-Pugh classes B and C)
A life-threatening illness, medical condition (including psychiatric conditions) or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety
Any life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk
A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ACP- (acalabrutinib), or put the study outcomes at undue risk
A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of acalabrutinib, or put the study outcomes at undue risk.
Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk.
A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of acalabrutinib and/or ACP-, or put the study outcomes at undue risk.
A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ACP-, or put the study outcomes at undue risk
A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of acalabrutinib, or put the study outcomes at undue risk.
Any life-threatening illness, medical condition, or organ system dysfunction which, in the Investigator's opinion, could compromise the participant's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subject's safety or put the study outcomes at undue risk
Current life-threatening illness, medical condition, or organ system dysfunction which, in the investigators opinion, could compromise the patients safety, or put the study at risk
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Any uncontrolled active systemic infection or any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Any uncontrolled active systemic infection or any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of entinostat capsules, or put the study outcomes at undue risk
Life-threatening illnesses other than AML, uncontrolled medical conditions or organ system dysfunction that, in the Investigator's opinion, could compromise the patient's safety or put the study outcomes at risk
Any life-threatening illness, medical condition, including uncontrolled diabetes mellitus (DM), or organ system dysfunction that, in the opinion of the investigator, could compromise the subject's safety or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigators opinion, could compromise the subjects safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk.
Current life-threatening illness, medical condition, or organ system dysfunction which, in the Investigators opinion, could compromise the patients safety, or put the study at risk; any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver or other organ system that may place the subject at undue risk to undergo therapy with ibrutinib
A life threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the individual's safety or interfere with the absorption or metabolism of ENTO
Current life-threatening illness, medical condition, or organ system dysfunction which, in the Investigators opinion, could compromise the patients safety, or put the study at risk
Presence of a life-threatening illness, medical condition, organ system dysfunction, or other factors
Life-threatening illness or organ system dysfunction compromising safety evaluation
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigators opinion, could compromise the subjects safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigators opinion, could compromise the subjects safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigators opinion, could compromise the subjects safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigators opinion, could compromise the subjects safety or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigators opinion, could compromise the subjects safety or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigators opinion, could compromise the subjects safety or put the study outcomes at undue risk
Patient has a life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subjects safety or put the study outcomes at undue risk
EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Any life threatening illness, medical condition, or organ system dysfunction that, in the investigators opinion, could compromise the subjects safety or put the study outcomes at undue risk
Life-threatening illnesses other than AML or MDS, uncontrolled medical conditions or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, or put the study outcomes at risk.
